FDAsafety guidance66% confidence
Cancer Clinical Trial Eligibility Criteria: Performance Status
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Lupin; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Women's Health · Contraceptive
- Sub-indication
- General
Related signal: Lupin's ANDA201446 for Levonorgestrel Receives FDA AP Status